PF-05280586

BIOLOGICAL2 trials

Sponsors

Pfizer

Conditions

Follicular LymphomaRheumatoid Arthritis

Phase 2

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

CompletedNCT01526057

PfizerRheumatoid Arthritis

Start: 2012-03-20End: 2014-05-07Updated: 2019-11-19

Phase 3

A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

CompletedNCT02213263

PfizerFollicular Lymphoma

Start: 2014-09-30End: 2018-04-19Updated: 2019-06-20

Related Papers

Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar.

2021-06-219 citations

Factors influencing infusion-related reactions following dosing of reference rituximab (RTX) and PF-05280586, a RTX biosimilar.

Journal of Clinical Oncology2020-05-20

A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera<sup>®</sup>) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL).

2020-04-0131 citations

A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)

Blood2018-11-297 citations

Comparative assessment of clinical response in patients with rheumatoid arthritis between PF‐05280586, a proposed rituximab biosimilar, and rituximab

British Journal of Clinical Pharmacology2016-08-1719 citations